Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 28;18(3):2220–2231. doi: 10.3892/ol.2019.10541

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Brands et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 4. — Treatment efficacy of pazopanib and pazopanib + cisplatin in PCI-1, PCI-9, PCI-13, PCI-52 and SCC-68 cell lines. Treatment efficacy was determined using crystal violet staining. The tyrosine kinase inhibitor was administered at a log2-dilution, and a constant concentration of cisplatin (IC50 value) was added during combination treatment. IC₅₀ values are indicated on the x-axis; (1) indicates mono-therapy, and (2) indicates combination therapy. A concentration-dependent effect was detected in all cell lines. IC₅₀, half inhibitory concentration.